Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.01 (5.71%)
Spread: 0.03 (17.647%)
Open: 0.175
High: 0.00
Low: 0.00
Prev. Close: 0.175
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

20 Aug 2020 11:33

RNS Number : 7285W
Nuformix PLC
20 August 2020
 

Nuformix plc

("Nuformix" or the "Group")

 

 

Result of Annual General Meeting held on 20 August 2020

 

 

Cambridge, UK - 20 August 2020: Nuformix plc (LSE:NFX) announces that all resolutions proposed at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:

 

 

Votes For

% of Votes Cast

Votes Against

% of Votes Cast

Votes Withheld1

1

To receive the annual report and accounts for the year ended 31 March 2020

160,439,143

97.06

4,859,946

2.94

3,215,648

2

To approve the remuneration report contained within the Annual Report for the year ended 31 March 2020

160,409,517

97.05

4,871,780

2.95

3,233,440

3

To re-appoint Jo Holland as a director

160,421,351

97.06

4,859,946

2.94

3,233,440

4

To re-appoint Christopher Blackwell as a director

139,069,040

82.53

29,447,905

17.47

17,792

5

To appoint Karl Keegan as a director

139,057,206

82.52

29,459,739

17.48

17,792

6

To re-appoint Haysmacintyre as auditor of the Company

160,439,143

97.06

4,859,946

2.94

3,215,648

7

To authorise the directors to determine the remuneration of the auditor

160,421,351

97.05

4,877,738

2.95

3,215,648

8

To authorise the directors to allot shares

139,069,040

84.13

26,230,049

15.87

3,215,648

9

Authority to disapply pre-emption without restriction as to use (Special Resolution)

139,069,040

84.13

26,230,049

15.87

3,215,648

10

Authority to disapply pre-emption for acquisitions or specified capital investments (Special Resolution)

148,518,064

84.99

26,230,049

15.01

3,215,648

11

To authorise the Company to purchase its own shares (Special Resolution)

169,876,333

97.21

4,871,780

2.79

3,215,648

12

To authorise the Company to call a general meeting on not less than 14 clear days' notice (Special Resolution)

148,506,230

84.98

26,241,883

15.02

3,215,648

 

 

1 A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.

In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will shortly be available for inspection at the National Storage Mechanism document viewing facility at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Enquiries:

 

Nuformix plc

Roger Jones, Company Secretary

Fleur Wood, Investor Relations

Email: fleur.wood@nuformix.com

 

 

+44 (0)1223 627222

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGBBLFLBVLXBBF
Date   Source Headline
1st Feb 20227:00 amRNSAdviser Appointments
31st Jan 20222:09 pmRNSDirector/PDMR Shareholding
31st Jan 202211:05 amRNSResult of General Meeting
17th Jan 20229:56 amRNSPosting of Circular and Notice of General Meeting
10th Jan 20224:23 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSHolding(s) in Company
14th Dec 20212:05 pmRNSSecond Price Monitoring Extn
14th Dec 20212:00 pmRNSPrice Monitoring Extension
14th Dec 20217:01 amRNSSubscription to raise £1.65 million
14th Dec 20217:00 amRNSHalf year Report
25th Nov 20217:00 amRNSPositive pre-clinical data on NXP002
17th Nov 20219:34 amRNSHolding(s) in Company
12th Nov 20217:00 amRNSNXP004 patent application filing
9th Nov 20217:00 amRNSDirectorate Change
4th Oct 20212:01 pmRNSPrice Monitoring Extension
16th Sep 20212:14 pmRNSDirector/PDMR Shareholding - Replacement
16th Sep 202112:47 pmRNSDirector/PDMR Shareholding
13th Sep 20217:00 amRNSLicensing agreement with Oxilio for NXP001
24th Aug 202111:57 amRNSResult of AGM
23rd Jul 20211:35 pmRNSPosting of Annual Report and Notice of AGM
22nd Jul 20217:00 amRNSLetter to shareholders re: Dr Anne Brindley
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
21st Jul 20217:00 amRNSDirectorate Change
15th Jul 20217:00 amRNSFinal results for the year ended 31 March 2021
10th Jun 20219:25 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSNotice of Allowance of Patent in US
1st Jun 20217:00 amRNSProject update - Progress on NXP002 and NXP004
24th May 20217:00 amRNSDirectorate Changes
12th May 202111:35 amRNSHolding(s) in Company
11th May 20211:51 pmRNSHolding(s) in Company
22nd Apr 20212:06 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 20213:30 pmRNSCorrection: Holding(s) in Company
8th Apr 202111:54 amRNSHolding(s) in Company
6th Apr 202110:38 amRNSHolding(s) in Company
30th Mar 20215:14 pmRNSHolding(s) in Company
29th Mar 202111:27 amRNSResult of General Meeting and Total Voting Rights
22nd Mar 20217:00 amRNSNXP001 (Oncology) - Exercise of Option by Oxilio
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:05 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20219:05 amRNSSecond Price Monitoring Extn
19th Mar 20219:00 amRNSPrice Monitoring Extension
11th Mar 20217:00 amRNSInitiation of research by Allenby Capital
10th Mar 202111:05 amRNSSecond Price Monitoring Extn
10th Mar 202111:00 amRNSPrice Monitoring Extension
10th Mar 20219:05 amRNSSecond Price Monitoring Extn
10th Mar 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.